Quorum Software is growing fast by adding to its suite of technology by making strategic acquisitions. Getty Images

A Houston software company specializing in cloud-based accounting and finance technology for oil and gas companies is growing at a rapid pace thanks to recent acquisitions.

Houston-based Quorum Software has grown its company over 100 employees last year, and Gene Austin, who was recently named CEO, says it's just the beginning.

The software solutions provider, which is a portfolio company of California-based private equity firm Thoma Bravo LLC since 2018, has big plans to continue the exponential growth with more acquisitions that diversify their portfolio of services and a Houston office expansion later this year.

According to Austin, he expects this growth spurred by M&A activity to double Quorum's revenue of $200 million in the next 3 to 5 years.

"We are always thinking about how to best serve our customers," Austin says. "We've made millions of dollars of investments in our support organization and cloud team services that are foundational to reinvigorate innovation and help our customers see how the future can unfold for them."

Courtesy of Quorum

Quorum is in the midst of a transformation into a software provider, focusing on cloud operations and digital software with significant acquisitions. Most recently, they launched OGsys on Demand, a cloud-based accounting software, after acquiring OGsys in August of 2019. The integration of OGsys expands the cloud-based capabilities for accounting products tailored for upstream medium-sized energy companies.

The launch was right on the heels of two other acquisitions that included Irving, Texas-based Archeio Technologies in June, a document classification smart search technology provider, and Pasadena, Texas-based Coastal Flow Measurement Inc. in March, a family of energy measurement services, one of which was Flow-Cal, a measurement data management software for oil and natural gas.

"Using innovation for us means not only acquiring new technologies but also investing in the right areas for our business and our current products," says Austin.

Quorum, who provides software solutions for a broad spectrum of energy companies' needs, from operations to accounting, plant management, and financial forecasting, began as a consulting firm more than 20 years ago. The company got its start with a customer-oriented structure for large oil and gas companies, known as enterprise organizations in the industry.

Eventually, the business transitioned to working with mid-size firms along with their larger set of clients. It was then when Quorum began to hear from clients their need for better accounting software that met the specific challenges of mid-size companies.

"Our products are designed to help our clients know much more about what's happening inside the business, making sure efficiency is possible," Austin tells InnovationMap. "We're doing that by using web applications that allow our clients to use mobile devices, that's a fairly new innovation in the energy world, we're trying to lead the way."

The focus on quick and efficient software technologies is reaping benefits for Quorum. Eighty percent of the largest oil and gas producers in the United States use Quorum, and its technology powers 80,000 miles of pipeline and that accounts for 80 percent of all-natural gas processed in the U.S.

"We believe because of the products we represent and the way we position our services, including our cloud-based accounting and financial application," Austin says. "We are well-positioned to help our clients do a great job of driving efficiency."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”